It looks like “Fidaxomicin (formerly OPT-80, PAR-101 or Difimicin),” is still looking very promising so be sure to keep searching for its new name, Fidaxomicin. [1]  Again, Fidaxomicin is a new drug soon to complete its last studies before applying for FDA approval.  It has been shown, so far, to a tiny bit more effective [...]

Read Full Post »

According to TheStreet.com [1], top-line results of Optimer’s phase III Opt-80 study are demonstrating higher cure rates and lower relapse rates when compared to vancomycin.
Cure Rates Similar
If you ask me, the cure rates were similar (88% versus 86%), but this is still fantastic news.  Currently, there are two antibiotics being widely used to treat C [...]

Read Full Post »